

"Express Mail" Label No. EV 346 923 910 US
Date of Deposit October 31, 2003

PATENT
Attorney Docket No.: 015270-008930US
Client Reference No.: 334-US-NEW3

I hereby certify that this is being deposited with the United States Postal Service "Express Mail Post Office to Address" service under 37 CFR 1.10 on the date indicated above and is addressed to:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

By: Rosemarie L. Calk

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Dale B. Schenk et al.

Application No.: Unassigned

Filed: Herewith

For: PREVENTION AND TREATMENT
OF SYNUCLEINOPATHIC DISEASE

Examiner: Unassigned

Art Unit: Unassigned

INFORMATION DISCLOSURE
STATEMENT UNDER 37 CFR §1.97 and
§1.98

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The references cited on the attached PTO/SB/08A and PTO/SB/08B forms are being called to the attention of the Examiner. Copies of the references are enclosed. It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.


As provided for by 37 CFR 1.97(g) and (h), no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information, and no inference should be made that the information and references cited are, or are considered to be material to patentability because they are in this statement. No inference

should be made that the information and references cited are prior art merely because they are in this statement.

Applicant believes that no fee is required for submission of this statement.

However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,


Rosemarie L. Celli
Reg. No. 42,397

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, Eighth Floor
San Francisco, California 94111-3834
Tel: 650-326-2400
Fax: 650-326-2422
RLC:crf
60072646.v1

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	Unassigned
				Filing Date	Filed Herewith
				First Named Inventor	Schenk, Dale B.
				Art Unit	Unassigned
				Examiner Name	Unassigned
				Attorney Docket Number	015270-008930US
Sheet	1	of	3		

[illegible][illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

60072646 v1

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	Unassigned
				Filing Date	Filed Herewith
				First Named Inventor	Schenk, Dale B.
				Art Unit	Unassigned
				Examiner Name	Unassigned
Sheet	2	of	3	Attorney Docket Number	015270-008930US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AG	CHAPMAN, P.F., "Model behaviour," <u>Nature</u> , 408:915-916 (2000).	
	AH	CONWAY et al., "Acceleration of oligomerization, not fibrillization, is a shared property of both α -synuclein mutations linked to early-onset Parkinson's disease: Implications for pathogenesis and therapy," <u>PNAS</u> , 97(2):571-576 (2000).	
	AI	DEMATTOIS et al., "Peripheral anti A β antibody alters CNS and plasma A β clearance and decreases brain A β burden in a mouse model of Alzheimer's disease," <u>PNAS</u> , 10:1-6 (2001).	
	AJ	ELAN, "Elan and AHP provide an update on the phase 2A Clinical Trial of AN-1782," Press Release of 1/28/02.	
	AK	ELAN, "Elan and Wyeth provide update on status of Alzheimer's collaboration," Press Release of 3/1/02.	
	AL	ESIRI, M.M., "Is an effective immune intervention for Alzheimer's disease in prospect?," <u>Trends in Pharmacological Sciences</u> , 22(1):2-3	
	AM	FRENKEL et al., "N-terminal EFRH sequence of Alzheimer's β -amyloid peptide represents the epitope of its anti-aggregating antibodies," <u>Journal of Neuroimmunology</u> , 88:85-90 (1998).	
	AN	FRENKEL et al., "Immunization against Alzheimer's β -amyloid plaques via EFRH phage administration," <u>PNAS</u> , 97(21):11455-11459 (2000).	
	AO	FRENKEL et al., "High affinity binding of monoclonal antibodies to the sequential epitope EFRH of β -amyloid peptide is essential for modulation of fibrillar aggregation," <u>Journal of Neuroimmunology</u> , 95:136-142 (1999).	
	AP	FRIEDLAND et al., "Neuroimaging of Vessel Amyloid in Alzheimer's Disease a,b," from <u>Cerebrovascular Pathology in Alzheimer's Disease</u> , eds. de la Torre and Hachinski, New York Academy of Science, NY, NY, pages 242-247 (1997).	
	AQ	GAMES et al., "Alzheimer-type neuropathology in transgenic mice overexpressing V717F β -amyloid precursor protein," <u>Nature</u> , 373(6514):523-527 (1995).	
	AR	GRUBECK-LOEBENSTEIN et al., "Immunization with β -amyloid: could T-cell activation have a harmful effect?," <u>TINS</u> , 23(3):114 (2000).	
	AS	JEN et al., "Preparation and purification of antisera against different regions or isoforms of β -amyloid precursor protein," <u>Brain Research Protocols</u> , 2:23-30 (1997).	
	AT	JOBLING et al., "Analysis of structure and function of the B subunit of cholera toxin by the use of site-directed mutagenesis," <u>Molecular Microbiology</u> , 5(7):1755-1767. (1991).	
	AU	LEMERE et al., "Nasal A β Treatment Induces Anti-A β Antibody Production and Decreases Cerebral Amyloid Burden in PD-APP Mice," <u>Annals of NY Acad. Sci.</u> , 920:328-331 (2000).	
	AV	MASLIAH et al., " β -Amyloid peptides enhance α -synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease," <u>PNAS</u> , 98(21):12245-12250 (2001).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	Unassigned
				Filing Date	Filed Herewith
				First Named Inventor	Schenk, Dale B.
				Art Unit	Unassigned
				Examiner Name	Unassigned
Sheet	3	of	3	Attorney Docket Number	015270-008930US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AW	PERUTZ et al., "Amyloid fibers are water-filled nanotubes," <u>PNAS</u> , 99(8):5591-5595 (2002).	
	AX	RASO, V., "Immunotherapy of Alzheimer's Disease," <u>Immunotherapy Weekly</u> , abstract, (1999).	
	AY	SCHENK et al., "Immunization with amyloid- β attenuates Alzheimer-disease-like pathology in the PDAPP mouse," <u>Nature</u> , 400:173-177 (1999).	
	AZ	SKOLNICK et al., "From genes to protein structure and function: novel applications of computational approaches in the genomic era," <u>Trends in Biotechnology</u> , 18(1):34-39 (2000).	
	BA	SMALL et al., "Alzheimer's disease and A β toxicity: from top to bottom," <u>Nat. Rev. Neurosci.</u> , 2(8):595-598 (2001).	
	BB	ST GEORGE-HYSLOP et al., "Antibody clears senile plaques," <u>Nature</u> , 400:116-117 (1999).	
	BC	YOUNKIN, S.G., "Amyloid β vaccination: reduced plaques and improved cognition," <u>Nature Medicine</u> , 7(1):18-19 (2001).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.